European principles of inhibitor management in patients with
haemophilia: implications of new treatment options

J 2020

European principles of inhibitor management in patients with haemophilia: implications of new treatment options

HERMANS, C., P. L. F. GIANGRANDE, B. O MAHONY, P. DE KLEIJN, M. BEDFORD et. al.

Základní údaje

Originální název

European principles of inhibitor management in patients with haemophilia: implications of new treatment options

Autoři

HERMANS, C. (56 Belgie), P. L. F. GIANGRANDE (56 Belgie), B. O MAHONY (56 Belgie), P. DE KLEIJN (528 Nizozemské království), M. BEDFORD (826 Velká Británie a Severní Irsko), A. BATOROVA (703 Slovensko), Jan BLATNÝ (203 Česká republika, domácí) a K. JANSONE (56 Belgie)

Vydání

Orphanet Journal of Rare Diseases, London, England, 2020, 1750-1172

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

10603 Genetics and heredity

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 4.123

Kód RIV

RIV/00216224:14110/20:00116531

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1186/s13023-020-01511-8

UT WoS

000567119900003

Klíčová slova anglicky

Haemophilia; Guidelines; Inhibitors; Factor VIII; Factor IX; Bypassing agents; Emicizumab; Immune tolerance

Štítky

14110321, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 30. 9. 2020 11:02, Mgr. Tereza Miškechová

Anotace

V originále

In light of the rapidly changing landscape of haemophilia treatment, the authors of the position paper on the “European Principles of Inhibitor Management” published in 2018 (Table 1) now provide an update on the major impact of novel therapies that bypass and/or substitute clotting factor VIII (FVIII) and IX (FIX) in the care of haemophilia patients with FVIII- or FIXneutralizing allo-inhibitory antibodies (inhibitors).

Citovat

HERMANS, C., P. L. F. GIANGRANDE, B. O MAHONY, P. DE KLEIJN, M. BEDFORD, A. BATOROVA, Jan BLATNÝ a K. JANSONE. European principles of inhibitor management in patients with haemophilia: implications of new treatment options. Orphanet Journal of Rare Diseases. London: England, 2020, roč. 15, č. 1, s. 1-4. ISSN 1750-1172. Dostupné z: https://dx.doi.org/10.1186/s13023-020-01511-8.

@article{1681836,
   author = {Hermans, C. and Giangrande, P. L. F. and O Mahony, B. and de Kleijn, P. and Bedford, M. and Batorova, A. and Blatný, Jan and Jansone, K.},
   article_location = {London},
   article_number = {1},
   doi = {http://dx.doi.org/10.1186/s13023-020-01511-8},
   keywords = {Haemophilia; Guidelines; Inhibitors; Factor VIII; Factor IX; Bypassing agents; Emicizumab; Immune tolerance},
   language = {eng},
   issn = {1750-1172},
   journal = {Orphanet Journal of Rare Diseases},
   title = {European principles of inhibitor management in patients with haemophilia: implications of new treatment options},
   url = {https://ojrd.biomedcentral.com/track/pdf/10.1186/s13023-020-01511-8},
   volume = {15},
   year = {2020}
}

TY  - JOUR
ID  - 1681836
AU  - Hermans, C. - Giangrande, P. L. F. - O Mahony, B. - de Kleijn, P. - Bedford, M. - Batorova, A. - Blatný, Jan - Jansone, K.
PY  - 2020
TI  - European principles of inhibitor management in patients with haemophilia: implications of new treatment options
JF  - Orphanet Journal of Rare Diseases
VL  - 15
IS  - 1
SP  - 1-4
EP  - 1-4
PB  - England
SN  - 17501172
KW  - Haemophilia
KW  - Guidelines
KW  - Inhibitors
KW  - Factor VIII
KW  - Factor IX
KW  - Bypassing agents
KW  - Emicizumab
KW  - Immune tolerance
UR  - https://ojrd.biomedcentral.com/track/pdf/10.1186/s13023-020-01511-8
L2  - https://ojrd.biomedcentral.com/track/pdf/10.1186/s13023-020-01511-8
N2  - In light of the rapidly changing landscape of haemophilia treatment, the authors of the position paper on the “European Principles of Inhibitor Management” published in 2018 (Table 1) now provide an update on the major impact of novel therapies that bypass and/or substitute clotting factor VIII (FVIII) and IX (FIX) in the care of haemophilia patients with FVIII- or FIXneutralizing allo-inhibitory antibodies (inhibitors).
ER  -

HERMANS, C., P. L. F. GIANGRANDE, B. O MAHONY, P. DE KLEIJN, M. BEDFORD, A. BATOROVA, Jan BLATNÝ a K. JANSONE. European principles of inhibitor management in patients with haemophilia: implications of new treatment options. \textit{Orphanet Journal of Rare Diseases}. London: England, 2020, roč.~15, č.~1, s.~1-4. ISSN~1750-1172. Dostupné z: https://dx.doi.org/10.1186/s13023-020-01511-8.

Podrobný výpis o publikaci